Clinical Trials Logo

Clinical Trial Summary

This is a phase 4 study to evaluate with Polysomnography (PSG) and subjective measures the effect of Rotigotine on sleep efficiency, maintenance, insomnia, nocturnal akinesia and night-time movement in bed, in patients with advanced Parkinson's disease.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01519882
Study type Interventional
Source UCB Pharma
Contact
Status Terminated
Phase Phase 4
Start date March 2012
Completion date January 2013

See also
  Status Clinical Trial Phase
Completed NCT01711866 - A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4
Completed NCT01744496 - Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain Phase 4
Completed NCT00141518 - DAPHNE (Duodopa in Advanced Parkinson's: Health Outcomes & Net Economic Impact) Phase 4